URBANDALE, Iowa, Feb. 2, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company advancing technologies designed to address rare, emerging and neglected diseases, today announced that Company management will present at the BIO CEO & Investor Conference on Monday, February 13, 2017, at 9:00 a.m. Eastern Time. The conference takes place February 13–14, 2017, at the Waldorf Astoria in New York, NY.
Management will discuss the Company's efforts to address unmet medical needs in five focus areas: Zika virus infection, spinal muscular atrophy (SMA), chronic pain, refractory glaucoma, and cancer.
Date: Monday, February 13th, 2017
Time: 9:00 a.m. Eastern Time
Location: Waldorf Astoria New York
Presentation Room: Louis XVI
Therapeutic Focus: Orphan/Rare Diseases
In addition to the scheduled presentation, management will be available for one-on-one meetings.
About BIO CEO & Investor Conference
Now in its 19th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities. Each year the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities.
About Spotlight Innovation Inc.
Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.
Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation's efforts to develop and commercialize its various technologies, and to achieve its stated benchmarks. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include: risks and uncertainties, such as the inability to finance the planned development of the technologies; the inability to hire appropriate staff to develop the technologies; unforeseen technical difficulties in developing the technologies; the inability to obtain regulatory approval for human use; competitors' therapies proving to be more effective, cheaper or otherwise more preferable; or, the inability to market a product. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spotlight-innovation-to-present-at-bio-ceo--investor-conference-on-february-13-2017-300400994.html
SOURCE Spotlight Innovation Inc.